293 related articles for article (PubMed ID: 31819501)
1. Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.
Si M; Zhang J; Cao J; Xie Z; Shu S; Zhu Y; Lang J
Onco Targets Ther; 2019; 12():10057-10075. PubMed ID: 31819501
[TBL] [Abstract][Full Text] [Related]
2. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
3. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
[TBL] [Abstract][Full Text] [Related]
4. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets.
Wu M; Shang X; Sun Y; Wu J; Liu G
PeerJ; 2020; 8():e8961. PubMed ID: 32419983
[TBL] [Abstract][Full Text] [Related]
6. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
7. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
Zhang H; Wu Y; Li H; Sun L; Meng X
Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
[TBL] [Abstract][Full Text] [Related]
8. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
Zhang L; Sun L; Zhang B; Chen L
Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
[TBL] [Abstract][Full Text] [Related]
9. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
10.
Liu J; Li S; Liang J; Jiang Y; Wan Y; Zhou S; Cheng W
Cancer Manag Res; 2019; 11():2379-2392. PubMed ID: 30988639
[TBL] [Abstract][Full Text] [Related]
11. Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses.
Wu Y; Xia L; Guo Q; Zhu J; Deng Y; Wu X
Cancer Manag Res; 2020; 12():5213-5223. PubMed ID: 32636682
[TBL] [Abstract][Full Text] [Related]
12. Elevated mRNA Expression Levels of NCAPG are Associated with Poor Prognosis in Ovarian Cancer.
Xu T; Dong M; Wang Z; Li H; Li X
Cancer Manag Res; 2020; 12():5773-5786. PubMed ID: 32765080
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel candidate genes and small molecule drugs in ovarian cancer by bioinformatics strategy.
Wei M; Bai X; Dong Q
Transl Cancer Res; 2022 Jun; 11(6):1630-1643. PubMed ID: 35836518
[TBL] [Abstract][Full Text] [Related]
14. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
Xu Z; Zhou Y; Cao Y; Dinh TL; Wan J; Zhao M
Med Oncol; 2016 Nov; 33(11):130. PubMed ID: 27757782
[TBL] [Abstract][Full Text] [Related]
15. Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysis.
Qin W; Yuan Q; Liu Y; Zeng Y; Ke D; Dai X; Shuai Y; Hu J; Shi H
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):983-994. PubMed ID: 34794761
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
17. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer.
Liu H; Zhou L; Cheng H; Wang S; Luan W; Cai E; Ye X; Zhu H; Cui H; Li Y; Chang X
Chin Med J (Engl); 2023 Dec; 136(24):2974-2982. PubMed ID: 37284741
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
19. Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments.
Chang X; Li D; Liu C; Zhang Z; Wang T
Cancer Cell Int; 2021 Apr; 21(1):193. PubMed ID: 33952272
[TBL] [Abstract][Full Text] [Related]
20. Identification of core genes in ovarian cancer by an integrative meta-analysis.
Li W; Liu Z; Liang B; Chen S; Zhang X; Tong X; Lou W; Le L; Tang X; Fu F
J Ovarian Res; 2018 Nov; 11(1):94. PubMed ID: 30453999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
